Blocking CCR10 Expression Activates m6A Methylation and Alleviates Vascular Endothelial Cell Injury

Area of Science:

• Cardiovascular research
• Molecular biology
• Genomics

Background:

• Cardiovascular disease (CVD) poses a significant global health risk.
• Human dermal microvascular endothelial cells (HDMECs) play a crucial role in vascular health.
• Understanding molecular mechanisms underlying endothelial cell injury is vital for CVD treatment.

Purpose of the Study:

• To investigate genome-wide changes in injured HDMECs using RNA sequencing (RNA-Seq).
• To identify key genes influencing N6-methyladenosine (m6A) methylation in cardiovascular disease.
• To explore potential therapeutic targets for CVDs.

Main Methods:

• RNA-sequencing (RNA-Seq) to analyze differentially expressed genes (DEGs) in endotoxin-injured HDMECs.
• Selection of DEGs associated with m6A methylation for functional analysis.
• Cellular assays including scratch, western blotting, and ELISA to assess cell migration, angiogenesis, and inflammation.

Main Results:

• RNA-Seq identified 20 DEGs, with C-C motif chemokine receptor 10 (CCR10) being significantly upregulated.
• Elevated CCR10 expression correlated with reduced m6A methylation in injured HDMECs.
• Blocking CCR10 enhanced m6A methylation, promoted cell activity, angiogenesis, and reduced inflammation.

Conclusions:

• Blocking CCR10 expression activates m6A methylation and alleviates HDMEC injury.
• CCR10 inhibition demonstrates potential for promoting cell activity and reducing inflammatory responses.
• Targeting CCR10 offers a promising therapeutic strategy for cardiovascular diseases.